EFPIA states AI rules must “enable not hinder” pharma R&D
Drug Discovery World
APRIL 24, 2024
The EFPIA supports the European Medicines Regulatory Network’s (EMRN) considered approach to AI, which builds on existing methods, good research practices, and requirements applied to other drug development tools (such as traditional statistical methods and approaches including model informed drug development).
130 
Let's personalize your content